Novartis gains European approval for ranibizumab

Article

Novartis will be the first company to offer licensed therapy ranibizumab to treat myopic choroidal neovascularisation (CNV).

Novartis will be the first company to offer licensed therapy ranibizumab to treat myopic choroidal neovascularisation (CNV).

Approval was granted after data from the Novartis-sponsored clinical trial RADIANCE. The study demonstrated that ranibizumab provides superior improvement in visual acuity compared to current treatment methods such as verteporfin PDT.

CND patients will receive one ranibizumab injection and further injections based on individual requirements. Monitoring is needed for at least two months, with retreatment administered based on vision and anatomical changes.

Mr Adnan Tufail, consultant ophthalmologist at Moorfields Eye Hospital, London, UK, said, “The use of Lucentis in the treatment of myopic CNV will significantly change how this condition is treated. Until now, this has been an area where there is high unmet medical need. At best we have only been able to stabilise vision and prevent further vision loss in people with myopic CNV with current licensed treatments.

“Lucentis is the first anti-VEGF therapy licensed for this condition and, as the clinical trials have shown, it can restore vision rapidly in some patients with just a few injections.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.